Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,336 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety profile of didanosine among patients with advanced HIV disease who are intolerant to or deteriorate despite zidovudine therapy: results of the Canadian Open ddI Treatment Program.
Montaner JS, Rachlis A, Beaulieu R, Gill J, Schlech W, Phillips P, Auclair C, Boulerice F, Schindzielorz A, Smaldone L, et al. Montaner JS, et al. Among authors: gill j. J Acquir Immune Defic Syndr (1988). 1994 Sep;7(9):924-30. J Acquir Immune Defic Syndr (1988). 1994. PMID: 7519674
Didanosine compared with continued zidovudine therapy for HIV-infected patients with 200 to 500 CD4 cells/mm3. A double-blind, randomized, controlled trial. Canadian HIV Trials Network Protocol 002 Study Group.
Montaner JS, Schechter MT, Rachlis A, Gill J, Beaulieu R, Tsoukas C, Raboud J, Cameron B, Salomon H, Dunkle L, Smaldone L, Wainberg MA. Montaner JS, et al. Among authors: gill j. Ann Intern Med. 1995 Oct 15;123(8):561-71. doi: 10.7326/0003-4819-123-8-199510150-00001. Ann Intern Med. 1995. PMID: 7677296 Clinical Trial.
Assay of HIV gp41 amino acid sequence to identify baseline variation and mutation development in patients with virologic failure on enfuvirtide.
Loutfy MR, Raboud JM, Montaner JS, Antoniou T, Wynhoven B, Smaill F, Rouleau D, Gill J, Schlech W, Brumme ZL, Mo T, Gough K, Rachlis A, Harrigan PR, Walmsley SL. Loutfy MR, et al. Among authors: gill j. Antiviral Res. 2007 Jul;75(1):58-63. doi: 10.1016/j.antiviral.2006.11.011. Epub 2006 Dec 18. Antiviral Res. 2007. PMID: 17196268
Results of antiretroviral treatment interruption and intensification in advanced multi-drug resistant HIV infection from the OPTIMA trial.
Holodniy M, Brown ST, Cameron DW, Kyriakides TC, Angus B, Babiker A, Singer J, Owens DK, Anis A, Goodall R, Hudson F, Piaseczny M, Russo J, Schechter M, Deyton L, Darbyshire J; OPTIMA Team. Holodniy M, et al. PLoS One. 2011 Mar 31;6(3):e14764. doi: 10.1371/journal.pone.0014764. PLoS One. 2011. PMID: 21483491 Free PMC article. Clinical Trial.
Evaluation of rapid progressors in HIV infection as an extreme phenotype.
Olson AD, Guiguet M, Zangerle R, Gill J, Perez-Hoyos S, Lodi S, Ghosn J, Dorrucci M, Johnson A, Sannes M, Moreno S, Porter K; for CASCADE Collaboration in EuroCoord. Olson AD, et al. Among authors: gill j. J Acquir Immune Defic Syndr. 2014 Sep 1;67(1):15-21. doi: 10.1097/QAI.0000000000000240. J Acquir Immune Defic Syndr. 2014. PMID: 24872130 Free PMC article.
3,336 results